Reis Gabriela Nagy Baldy Dos, Cuba Gabriel Trova, Targa Walter Hamilton DE Castro, Miras Paulo Sérgio Contador, Bongiovanni José Carlos, Salles Mauro José, Reis Fernando Baldy Dos, Dell'aquila Adriana Macedo
Universidade Federal de São Paulo, Department of Orthopedics and Traumatology, São Paulo, SP, Brazil.
Universidade Federal de São Paulo, Paulista School of Medicine, São Paulo, SP, Brazil.
Acta Ortop Bras. 2023 Feb 20;31(1):e258453. doi: 10.1590/1413-785220233101e258453. eCollection 2023.
Evaluating the clinical results of bioactive glass S53P4 putty for the treatment of cavitary chronic osteomyelitis.
Retrospective observational study, including patients of any age with clinical and radiological diagnosis of chronic osteomyelitis, who underwent surgical debridement and implantation of bioactive glass S53P4 putty (BonAlive Putty, Turku, Finland). Patients who underwent any plastic surgery on the soft tissues of the affected site or had segmental bone lesions or septic arthritis were excluded. Statistical analysis was performed using Excel. Demographic data, as well as data on the lesion, treatment, and follow-up, were collected. Outcomes were classified as "disease-free survival," "failure," or "indefinite."
This study included 31 patients, of which 71% were men and had with a mean age of 53.6 years (SD ± 24.2). In total, 84% were followed-up for at least 12 months and 67.7% had comorbidities. We prescribed combination antibiotic therapy for 64.5% of patients. In 47.1%, was isolated. Finally, we classified 90.3% of cases as "disease-free survival" and 9.7% as "indefinite."
Bioactive glass S53P4 putty is safe and effective to treat cavitary chronic osteomyelitis, including infections by resistant pathogens, such as methicillin-resistant .
评估生物活性玻璃S53P4糊剂治疗空洞性慢性骨髓炎的临床效果。
回顾性观察研究，纳入临床及影像学诊断为慢性骨髓炎的各年龄段患者，这些患者接受了手术清创并植入生物活性玻璃S53P4糊剂（BonAlive糊剂，芬兰图尔库）。排除在患部软组织进行过任何整形手术、有节段性骨病变或化脓性关节炎的患者。使用Excel进行统计分析。收集人口统计学数据以及病变、治疗和随访数据。结果分为“无病生存”“失败”或“不确定”。
本研究纳入31例患者，其中71%为男性，平均年龄53.6岁（标准差±24.2）。总体而言，84%的患者随访至少12个月，67.7%的患者有合并症。64.5%的患者接受了联合抗生素治疗。47.1%的患者分离出了[具体病原体未明确写出]。最后，我们将90.3%的病例分类为“无病生存”，9.7%分类为“不确定”。
生物活性玻璃S53P4糊剂治疗空洞性慢性骨髓炎安全有效，包括耐甲氧西林[具体病原体未明确写出]等耐药病原体引起的感染。
